In this episode of DeviceTalks, we speak with Richard Thompson, CEO of ReShape Medical, about the company’s bariatric surgery alternative for people suffering from obesity. In July, San Clemente, Calif.-based ReShape won pre-market approval from the FDA for its dual balloon system, indicated to facilitate weight loss in obese adult patients. The system is designed to be inserted […]
ReShape Medical said today it closed a $38 million Series D round of financing, with funds slated to support the commercialization of its ReShape integrated dual balloon weight-loss system. The round was led by HealthCor Partners Management and included participation from Endeavour Vision SA, SV Life Sciences, New Leaf Venture Partners, U.S. Venture Partners and […]
Weight loss company ReShape Medical won FDA premarket approval for its ReShape dual balloon system, indicated to facilitate weight loss in obese adult patients, according to an FDA release. The system is designed to be inserted endoscopically into the stomach, where it remains for 6 months to help patients feel full, San Clemente, Calif.-based ReShape […]
JenaValve said this week that it tapped Victoria Carr-Brendel, former general manager of Boston Scientific‘s (NYSE:BSX) Bayer Interventional business, as its new chief executive officer. Carr-Brendel will replace Jan Keltjens, who served as interim CEO of the transcatheter aortic valve repair-focused company since January 2015. Keltjens will remain with the company as chairman of the board, JenaValve said. […]
ReShape Medical, which is developing a balloon system to combat obesity, notched a significant victory in its path to commercialization, CEO Richard Thompson told MassDevice.com today.
Regulators at the FDA waived a requirement that the San Clemente, Calif.-based company appear before an advisory committee for its premarket approval application, Thompson told us. That removes a significant amount of uncertainty from the arduous PMA process for the ReShape Duo device, he said.
ReShape Medical, the medical device maker developing a balloon system to combat obesity has raised nearly $7 million through a debt financing round, according to regulatory filings.
MASSDEVICE ON CALL — BioVentrix reported a $12.4 million funding round for its Revivent heart failure treatment.
San Ramon, Calif.-based BioVentrix said in an equity filing that the equity round, involving 195 unnamed investors, began Jan. 24 and closed today.
San Clemente, Calif.-based ReShape Medical closed pivotal trial enrollment for its ReShape Duo non-surgical weight-loss system, the company announced this week.
ReShape’s Duo system is comprised of dual intra-gastric balloons that are placed in the stomach non-surgically via an endoscope inserted into the mouth. The balloons takes up space in the stomach to help patients feel full faster, causing them to eat smaller portions.
ReShape Medical reeled in $15.8 million of a hoped-for $21.5 million funding round from a group of 7 unnamed investors, according to a regulatory filing.
The San Clemente, Calif.-based medical device company is developing a non-surgical weight loss device, the ReShape Duo, to treat obese patients. The device is a dual balloon designed to take up space in the stomach to reduce its capacity for food.